2017 | 2016 | 2015
DateTitle 
12/13/17Luminex Corporation Declares Fourth Quarter Cash Dividend
AUSTIN, Texas, Dec. 13, 2017 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the fourth quarter of 2017 of $0.06 per share of common stock payable on January 12, 2018 to stockholders of record as of the close of business on December 22, 2017. About Luminex Corporation At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a... 
Printer Friendly Version
11/14/17Luminex Corporation To Present At The 29th Annual Piper Jaffray Healthcare Conference
AUSTIN, Texas, Nov. 14, 2017 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that management will present at the 29th Annual Piper Jaffray Healthcare Conference to be held November 28 -29, 2017, in New York. The investor presentation will begin at 8:00 a.m. Eastern time on Wednesday, November 29, 2017.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go ... 
Printer Friendly Version
10/31/17Luminex Corporation Receives FDA Clearance for ARIES Group A Strep Assay
Expands Portfolio of IVD Respiratory Tests on the ARIES Systems AUSTIN, Texas, Oct. 31, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Group A Strep Assay, a moderate complexity, sample to answer test for the direct detection of Streptococcus pyogenes from throat swab specimens using the ARIES® System. This is the sixth assay the FDA has cleared for use on Luminex's ARIES® Systems in the last 24 months. ... 
Printer Friendly Version
10/30/17Luminex Corporation Reports Third Quarter 2017 Financial Results
AUSTIN, Texas, Oct. 30, 2017 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced financial results for the third quarter of 2017.  Financial and operating highlights for the quarter include the following: Consolidated revenue of $74.1 million, an increase of 4% compared to the third quarter 2016. Assay revenue was $37.9 million for the quarter ended September 30, 2017, representing a 17% increase over assay revenue for the third quarter of 2016. Total sample-to... 
Printer Friendly Version
10/09/17Luminex Corporation Third Quarter Earnings Release Scheduled for October 30, 2017
AUSTIN, Texas, Oct. 9, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the third quarter ended September 30, 2017 on Monday, October 30, 2017. A press release announcing the results is scheduled for release after the close of trading on that date. Management will hold a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2017 on October 30, 2017, at 4:30 p.m. Eastern ... 
Printer Friendly Version
09/19/17Luminex Corporation To Present At Cantor Fitzgerald's Global Healthcare Conference
AUSTIN, Texas, Sept. 19, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at Cantor Fitzgerald's Global Healthcare Conference to be held September 25 -27, 2017, in New York, NY. The investor presentation will begin at 10:20 a.m. Eastern time on Tuesday, September 26, 2017.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, ... 
Printer Friendly Version
09/12/17Luminex Corporation Declares Third Quarter Cash Dividend
AUSTIN, Texas, Sept. 12, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the third quarter of 2017 of $0.06 per share of common stock payable on October 13, 2017 to stockholders of record as of the close of business on September 22, 2017. About Luminex Corporation At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a... 
Printer Friendly Version
08/29/17Luminex Corporation and Sutter Health Collaborate to Improve Patient Care
Northern California healthcare system employing multiple Luminex diagnostic systems to improve its laboratory services for the community AUSTIN, Texas, Aug. 29, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX), and Sutter Health, a not-for-profit health system in Northern California, today announced a collaboration to help advance patient care by improving the health network's ability to quickly and accurately diagnose a range of conditions, including Cystic Fibrosis, gastrointestina... 
Printer Friendly Version
08/07/17Luminex Corporation Reports Second Quarter 2017 Financial Results
AUSTIN, Texas, Aug. 7, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the second quarter of 2017.  Financial and operating highlights for the quarter include the following: Consolidated revenue of $76.5 million, an increase of 19% compared to the second quarter 2016.  Total automated sample to answer molecular product revenue of $10.7 million; pro-forma growth of 44% compared to $7.4 million in the second quarter of 2016. 270 mult... 
Printer Friendly Version
07/24/17Luminex Corporation Receives FDA Clearance for ARIES C. difficile Assay
Sample to answer test provides detection of both toxin A and B AUSTIN, Texas, July 24, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® C. difficile Assay, a moderate complexity, sample to answer test for rapid detection of C. difficile. The ARIES® C. difficile Assay detects both toxin A and toxin B, which may reduce the probability of a false negative result from strains that only produce toxin A. This milestone ... 
Printer Friendly Version
07/17/17Luminex Corporation Second Quarter Earnings Release Scheduled for August 7, 2017
AUSTIN, Texas, July 17, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the second quarter ended June 30, 2017 on Monday, August 7, 2017. A press release announcing the results is scheduled for release after the close of trading on that date. Management will hold a conference call to discuss the operating highlights and financial results for the second quarter ended June 30, 2017 on August 7, 2017, at 4:30 p.m. Eastern time. T... 
Printer Friendly Version
06/28/17Luminex Corporation Receives CE-IVD Mark for ARIES® Norovirus Assay
Easy to use, sample to answer assay provides rapid detection of leading cause of acute gastroenteritis AUSTIN, Texas, June 28, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for the ARIES® Norovirus Assay, an easy to use, sample to answer test for rapid detection and differentiation of norovirus genogroup I and II from stool specimens of individuals with symptoms of acute gastroenteritis. The CDC reports that norovi... 
Printer Friendly Version
06/05/17Luminex Corporation's VERIGENE Gram-Positive and Gram-Negative Blood Culture Panels Receive Reimbursement Approval in Japan
Molecular Assays Shorten Times to Results and Improve Management of Infectious Diseases AUSTIN, Texas, June 5, 2017 /PRNewswire/ --Luminex Corporation (NASDAQ: LMNX) today announced that Japan's Central Social Insurance Medical Council has approved the recommendation by the Japanese Ministry of Health, Labor and Welfare (MHLW) to provide reimbursement for two VERIGENE® assays: the Gram-Positive Blood Culture (BC-GP) test and the Gram-Negative Blood Culture (BC-GN) test. ... 
Printer Friendly Version
05/25/17Luminex Corporation To Present At Jefferies 2017 Global Healthcare Conference
AUSTIN, Texas, May 25, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Jefferies 2017 Global Healthcare Conference on Thursday, June 8 at 8:30am ET in New York. The investor presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at leas... 
Printer Friendly Version
05/24/17Luminex Corporation Declares Second Quarter Cash Dividend
AUSTIN, Texas, May 24, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the second quarter of 2017 of $0.06 per share of common stock payable on July 14, 2017 to stockholders of record as of the close of business on June 23, 2017. About Luminex Corporation At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide ran... 
Printer Friendly Version
05/03/17Luminex Corporation Receives FDA Clearance for ARIES Bordetella Assay
Sample to answer assay provides accurate pertussis surveillance of clinically symptomatic patients AUSTIN, Texas, May 3, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Bordetella Assay for direct detection and identification of Bordetella pertussis (B. pertussis) and Bordetella parapertussis (B. parapertussis) nucleic acid in nasopharyngeal swab specimens obtained from individuals suspected of having a respirato... 
Printer Friendly Version
05/01/17Luminex Corporation Reports Record First Quarter 2017 Financial Results; Raises 2017 Financial Guidance
AUSTIN, Texas, May 1, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter of 2017.  Financial and operating highlights for the quarter include the following: Consolidated revenue of $77.8 million, an increase of 23% compared to the first quarter 2016.  Total Verigene related revenue of $10.5 million; growth of 59% over its first quarter 2016. Corporate gross margin increased to 68% from 61% in the fourth quarter, 2016... 
Printer Friendly Version
04/26/17Luminex Corporation To Present At The Deutsche Bank 42nd Annual Health Care Conference
AUSTIN, Texas, April 26, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3, 2017 at 10:00am ET in Boston, Massachusetts. The investor presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Pleas... 
Printer Friendly Version
04/20/17Luminex Corporation To Present At Bank Of America Merrill Lynch 2017 Health Care Conference
AUSTIN, Texas, April 20, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Bank of America Merrill Lynch 2017 Health Care Conference on Tuesday, May 16 at 1:40pm PT in Las Vegas. The investor presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the... 
Printer Friendly Version
04/10/17Luminex Corporation First Quarter Earnings Release Scheduled for May 1, 2017
AUSTIN, Texas, April 10, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the first quarter ended March 31, 2017 on Monday, May 1, 2017. A press release announcing the results is scheduled for release after the close of trading on that date. Management will hold a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2017 on May 1, 2017, at 4:30 p.m. Eastern time. The co... 
Printer Friendly Version
03/01/17Luminex Corporation To Present At The Barclays Global Healthcare Conference
AUSTIN, Texas, March 1, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Barclays Global Healthcare Conference to be held at the Loews Miami Beach Hotel March 14 - 16, 2017, in Miami Beach, FL. The investor presentation will begin at 4:20 p.m. Eastern time on Wednesday, March 15, 2017.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply... 
Printer Friendly Version
02/21/17Luminex Corporation Announces Initiation of Cash Dividend
AUSTIN, Texas, Feb. 21, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) (the "Company") today announced that its board of directors has authorized the initiation of a quarterly cash dividend to its shareholders, the first in the company's history.  This initial cash dividend will be payable on April 14, 2017 to shareholders of record as of the close of business on March 24, 2017. The board of directors intends for the Company to pay a regular quarterly cash dividend o... 
Printer Friendly Version
02/06/17Luminex Corporation Reports Fourth Quarter And Full Year 2016 Results
AUSTIN, Texas, Feb. 6, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and full year 2016 ended December 31, 2016.  Financial and operating highlights include the following: Consolidated fourth quarter and full year 2016 revenue of $72.3 million and $270.6 million, an increase of 20% and 14% compared to the fourth quarter and full year 2015.  In the fourth quarter, Nanosphere contributed revenue of $9.5 millio... 
Printer Friendly Version
01/09/17Luminex Announces Preliminary Revenue for Fourth Quarter 2016 and Issues 2017 Revenue Guidance; To Present at 35th Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas, Jan. 9, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects revenues in the fourth quarter of 2016 to be approximately $72 million and approximately $271 million for the year. These results reflect increases of 20% and 14% compared to the respective periods in 2015. Verigene-related revenues in the fourth quarter were approximately $9 million, a 32% increase from the year ago period. The company conducted a reorganization in Decem... 
Printer Friendly Version
01/04/17Luminex Corporation Receives FDA Clearance for ARIES® GBS Assay
Sample to answer GBS assay offers higher sensitivity and specificity compared to culture AUSTIN, Texas, Jan. 4, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Group B Streptococcus (GBS) Assay for antepartum detection of GBS colonization in pregnant women. This is the third assay the FDA has cleared for use on the Luminex ARIES® Systems. The company has also achieved CE-IVD marking for the ARIES® GBS Assay... 
Printer Friendly Version